This market is very much fragmented in nature with the presence of international and local players.
- Advertising -
According to a new market research report, the Global Non-Invasive Prenatal Testing Market to grow from USD 1.46 billion in 2016 to touch USD 3.01 billion by 2021 at a CAGR of 15.6%.
Browse Full Report @ www.orbisresearch.com/reports/inde…orecasts-20162021
Non-Invasive Prenatal Testing (NIPT) is a new type of genetic test that screens for inherited diseases and birth defects. It generally involves a simple blood screening that analyses the DNA, known as cell-free DNA(cf-DNA) to precisely estimate a baby’s risk for a variety of genetic disorders, such as Down syndrome.
The growth of the Global Non-Invasive Prenatal Testing Market is mainly driven by factors such as the introduction of newer and more advanced NIPT products, the feasibility and growing preference for non-invasive techniques over invasive ones, increasing risk of chromosomal abnormalities in babies with growing maternal age and favourable reimbursement for NIPT.
- Advertising -
Key companies are playing a major role I expanding the boundaries of cf-DNA studies with attempts being at identifying about 20,000 genetic feature through a single sample in a single reaction. The possibilities of false positives coupled with the lower clinical validity of particularly the micro deletion segment are among the major restraints of the market.
The market has been geographically segmented into North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa. North America leads the market in 2016, with the U.S.
accounting for a major share. North America’s lead is justified by the presence of high-end technology, it being a developed market combined with the growing incidence of genetic abnormalities.
Europe comes in second in terms of market share owing to the rising awareness and establishment of MIPT procedures. However, Asia-Pacific is estimated to grow at the highest CAGR during the forecast period majorly because of the presence of exponentially greater population numbers.
The Non-Invasive Prenatal Testing Market is very much fragmented in nature with the presence of international and local players. The noticeable players in the market implement various strategies such as product launches, and approvals, product innovation, R&D investment for advancement in Non-Invasive Prenatal Testing, with acquisitions, and mergers as their developmental strategies to endure the competitive setting of the market.
The key players in the Non-Invasive Prenatal Testing Market are GE Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.), and Beijing Genomics Institute (China.
Request Sample Pages @ www.orbisresearch.com/contacts/request-sample/391611
The Global Non-Invasive Prenatal Testing Market is segmented based on Instruments, Method of Screening, Application, End User and geography. Based on Instruments, the market is divided into Ultrasound, NGS, PCR and Microarray.
Based on Method, the Non-Invasive Prenatal Testing Market is segmented into FCMB and cf-DNA. Further, by Application, the market is branched into Trisomy, Micro deletion, Genetics, and Rh factor.
Based on the End User, it is categorized into Hospital and Diagnostic Labs.
Category: Market Research Publishers and RetailersCompany profile: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have a vast database of reports from the leading publishers and authors across the gl obe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their need, and we produce the perfect requi ...
For more information: